For research use only. Not for therapeutic Use.
AKR1C3-IN-9 is a selective inhibitor of Aldo-keto Reductase 1C3 (AKR1C3) with an IC50 value of 8.92 nM. AKR1C3-IN-9 significantly reverses the Doxorubicin (HY-15142A) (DOX) resistance in a resistant breast cancer cell line[1].
AKR1C3-IN-9 (compound 24) (10-100 μM; 72 h and 96 h) results weak antiproliferative effect up to 100 μM in all three breast cancer cell lines (MDA-MB-231, MCF-7)[1].
AKR1C3-IN-9 (10 μM, 25 μM, and 50 μM; 72 h) synergistically inhibits the proliferation of MCF-7 cell with 10-50 μM DOX[1].
AKR1C3-IN-9 (10 μM; 8 d) synergistically inhibits the proliferation, clonogenic survival of MCF-7/DOX cell line, thus restores the sensitivity to DOX[1].
| Catalog Number | I042057 |
| CAS Number | 2924824-43-9 |
| Synonyms | 2-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-N-(2-methoxyphenyl)benzamide |
| Molecular Formula | C20H20N2O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H20N2O4/c1-13-16(14(2)26-22-13)12-25-18-10-6-4-8-15(18)20(23)21-17-9-5-7-11-19(17)24-3/h4-11H,12H2,1-3H3,(H,21,23) |
| InChIKey | JUPXIAWRJFYWOF-UHFFFAOYSA-N |
| SMILES | CC1=C(C(=NO1)C)COC2=CC=CC=C2C(=O)NC3=CC=CC=C3OC |
| Reference | [1]. Liu Y, et al. Development of highly potent and specific AKR1C3 inhibitors to restore the chemosensitivity of drug-resistant breast cancer. Eur J Med Chem. 2022 Dec 13;247:115013. |
